ClinicalTrials.gg
CompletedNCT00623233Updated Jan 9, 2012Results posted

Gemcitabine Plus Bevacizumab in Locally Recurrent or Metastatic Breast Cancer

A Phase 2 interventional study of Gemcitabine and Bevacizumab in Metastatic Breast Cancer and Locally Advanced Breast Cancer, sponsored by Eli Lilly and Company. Completed at 16 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-01-09.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
52
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 95 studies testing gemcitabine in Breast Neoplasms — 2 open to participants now, 5 under way, 3 of them phase 3. Gemcitabine · Breast Neoplasms.

Enrollment
55th of 90
52 · median 68
Started
2008
with 4 others
Phase 2
65 of 95
none open now
Registered
60th of 95
by date
Lead sponsor
20 of 95
Eli Lilly and Company

Among the 95 studies testing gemcitabine in Breast Neoplasms, this one is the 55th largest by enrollment of the 90 interventional ones that give a count, is one of 5 that started in 2008, is one of 65 in phase 2, and was the 60th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

2 of the 95 studies testing gemcitabine in Breast Neoplasms are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About gemcitabine

Gemcitabine: first FDA approval 1996 (GEMZAR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 95 studies testing gemcitabine in Breast Neoplasms, or all of them as a file.
02

Study summary

To determine how long Gemcitabine and Bevacizumab will stop the cancer from growing in patients with advanced breast cancer.

03

Conditions studied

  • Metastatic Breast Cancer
  • Locally Advanced Breast Cancer

Browse trials for

Keywords

  • Breast Neoplasm
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must be female and greater than or equal to 18 yrs of age
  • Participants must have confirmed cancer with measurable or evaluable, locally recurrent or disease.
  • Participants must have received a taxane as and/or adjuvant therapy
  • Participants may have received prior hormone therapy for locally recurrent or metastatic disease

Exclusion criteria

Exclusion Criteria:

  • Participants with breast cancer overexpressing Human Epidermal growth factor Receptor 2 () gene amplification
  • Prior chemotherapy or targeted therapy for breast cancer
  • Prior treatment with gemcitabine, trastuzumab, lapatinib or bevacizumab in any setting
  • History of, or active brain mets
  • Major surgical procedure, open , or significant traumatic injury within 28 days prior to treatment, or anticipation of need for major surgical procedure during course of study
  • Prior history of high blood pressure crisis
  • Have a serious, nonhealing wound, ulcer, or bone fracture
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
52 participants (actual)

Study arms

  • Experimental
    Gemcitabine + Bevacizumab

    Gemcitabine 2500 milligrams per square meter (mg/m\^2) intravenous (IV) over 30 minutes given on Day 1 every 14 days (q 14 days) until disease progression (PD) or unacceptable toxicity. Bevacizumab 10 milligrams per kilogram (mg/kg) initially over 90 minutes given on Day 1 q 14 days until PD or unacceptable toxicity.

    Drug: Gemcitabine · Drug: Bevacizumab

Interventions

  • Gemcitabine 2500 mg/m\^2 IV over 30 minutes given on Day 1 q 14 days prior to bevacizumab until PD or unacceptable toxicity.

    Also known as: Gemzar, LLY188011

  • Bevacizumab 10 mg/kg IV over 90 minutes at Cycle 1; infusion time may have been decreased for subsequent cycles. (For example, if the first infusion was tolerated without an infusion-associated adverse event \[AE\], the second infusion was delivered over 60 minutes. If the 60-minute infusion was well tolerated, all subsequent infusions were delivered over 30 minutes.) Bevacizumab 10 mg/kg initially over 90 minutes given on Day 1 q 14 days until PD or unacceptable toxicity.

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS) Time

    PFS was measured from date of first dose to first date of progressive disease (PD) or death from any cause. For each participant who was not known to have died or to have had PD as of the data inclusion cut-off date for a particular analysis, PFS duration was censored for that analysis at the date of the participant's last progression-free tumor assessment before that cut-off date.

    Time frame: Baseline to measured PD or death from any cause. Tumor assessments were performed every 8 weeks during therapy and every 2 months during post-therapy until documented PD (up to 34 months).

Secondary outcomes

  1. Overall Tumor Response Rate (ORR)

    Response defined per Response Evaluation Criteria In Solid Tumors (RECIST) criteria: complete response (CR)=disappearance of all target lesions; partial response (PR)=30% decrease in sum of longest diameter of target lesions; progressive disease (PD)=20% increase in sum of longest diameter of target lesions; stable disease=small changes that do not meet above criteria. ORR=proportion of participants who achieved a confirmed best response of CR or PR (responders). ORR=number of participants with CR or PR /number of participants qualified for tumor response analysis (per protocol population).

    Time frame: Baseline to measured PD. Tumor assessments were performed every 8 weeks (q 8 weeks) during therapy and q 2 months during post-therapy until documented PD (up to 34 months).

  2. Number of Participants With Adverse Events (AEs); Pharmacology Toxicities

    A listing of serious adverse events (SAEs) and other non-serious AEs is located in the Reported Adverse Event module.

    Time frame: Baseline, every cycle (every 14 days) up to 34 months

  3. 1-Year Overall Survival (OS) Rate

    OS was measured from the date of first dose to the date of death from any cause. For each participant who was not known to have died as of the data inclusion cut-off date for a particular analysis, OS duration was censored for that analysis at the date of participant's last study contact prior to that cut-off date. The 1-year survival rate (percentage of participants who were alive at 1 year) was estimated from OS data.

    Time frame: Baseline to death from any cause, 1 year

07

Results

Posted Jan 9, 2012

Participant flow

Participant flow — Overall Study
MilestoneGemcitabine 2500 mg/m^2 + Bevacizumab 10 mg/kg
Started52
Completed28
Not completed24
Withdrew: Adverse event10
Withdrew: Physician decision10
Withdrew: Lost to follow-up1
Withdrew: Withdrawal by subject3

Outcome measures

PrimaryProgression Free Survival (PFS) Time

PFS was measured from date of first dose to first date of progressive disease (PD) or death from any cause. For each participant who was not known to have died or to have had PD as of the data inclusion cut-off date for a particular analysis, PFS duration was censored for that analysis at the date of the participant's last progression-free tumor assessment before that cut-off date.

Time frame:
Baseline to measured PD or death from any cause. Tumor assessments were performed every 8 weeks during therapy and every 2 months during post-therapy until documented PD (up to 34 months).
Reported as:
Median · months
Progression Free Survival (PFS) Time
monthsGemcitabine 2500 mg/m^2 + Bevacizumab 10 mg/kg
Progression Free Survival (PFS) Time4.80 (3.42 to 7.56)
SecondaryOverall Tumor Response Rate (ORR)

Response defined per Response Evaluation Criteria In Solid Tumors (RECIST) criteria: complete response (CR)=disappearance of all target lesions; partial response (PR)=30% decrease in sum of longest diameter of target lesions; progressive disease (PD)=20% increase in sum of longest diameter of target lesions; stable disease=small changes that do not meet above criteria. ORR=proportion of participants who achieved a confirmed best response of CR or PR (responders). ORR=number of participants with CR or PR /number of participants qualified for tumor response analysis (per protocol population).

Time frame:
Baseline to measured PD. Tumor assessments were performed every 8 weeks (q 8 weeks) during therapy and q 2 months during post-therapy until documented PD (up to 34 months).
Reported as:
Number · proportion of responders
Overall Tumor Response Rate (ORR)
proportion of respondersGemcitabine 2500 mg/m^2 + Bevacizumab 10 mg/kg
Overall Tumor Response Rate (ORR)0.214 (0.1030 to 0.3681)
SecondaryNumber of Participants With Adverse Events (AEs); Pharmacology Toxicities

A listing of serious adverse events (SAEs) and other non-serious AEs is located in the Reported Adverse Event module.

Time frame:
Baseline, every cycle (every 14 days) up to 34 months
Reported as:
Number · participants
Number of Participants With Adverse Events (AEs); Pharmacology Toxicities
participantsGemcitabine 2500 mg/m^2 + Bevacizumab 10 mg/kg
SAEs18
Other non-serious AEs51
Secondary1-Year Overall Survival (OS) Rate

OS was measured from the date of first dose to the date of death from any cause. For each participant who was not known to have died as of the data inclusion cut-off date for a particular analysis, OS duration was censored for that analysis at the date of participant's last study contact prior to that cut-off date. The 1-year survival rate (percentage of participants who were alive at 1 year) was estimated from OS data.

Time frame:
Baseline to death from any cause, 1 year
Reported as:
Number · percentage of participants
1-Year Overall Survival (OS) Rate
percentage of participantsGemcitabine 2500 mg/m^2 + Bevacizumab 10 mg/kg
1-Year Overall Survival (OS) Rate68.68 (54.05 to 79.50)

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Gemcitabine 2500 mg/m^2 + Bevacizumab 10 mg/kg—18/52 (34.6%)51/52 (98.1%)
Most frequent serious events
Showing 10 of 44
Most frequent serious events
EventGemcitabine 2500 mg/m^2 + Bevacizumab 10 mg/kg
AnaemiaBlood and lymphatic system disorders2/52
VomitingGastrointestinal disorders2/52
SepsisInfections and infestations2/52
HypovolaemiaMetabolism and nutrition disorders2/52
Renal Failure AcuteRenal and urinary disorders2/52
Pleural EffusionRespiratory, thoracic and mediastinal disorders2/52
Febrile NeutropeniaBlood and lymphatic system disorders1/52
Haemolytic Uraemic SyndromeBlood and lymphatic system disorders1/52
LeukopeniaBlood and lymphatic system disorders1/52
NeutropeniaBlood and lymphatic system disorders1/52
Most frequent other events
Showing 10 of 50
Most frequent other events
EventGemcitabine 2500 mg/m^2 + Bevacizumab 10 mg/kg
NauseaGastrointestinal disorders32/52
FatigueGeneral disorders32/52
ConstipationGastrointestinal disorders21/52
AnaemiaBlood and lymphatic system disorders16/52
Decreased AppetiteMetabolism and nutrition disorders15/52
DyspnoeaRespiratory, thoracic and mediastinal disorders15/52
NeutropeniaBlood and lymphatic system disorders14/52
VomitingGastrointestinal disorders14/52
ProteinuriaRenal and urinary disorders13/52
DiarrhoeaGastrointestinal disorders12/52

Baseline characteristics

Age Continuous
Age Continuous(years)Gemcitabine 2500 mg/m^2 + Bevacizumab 10 mg/kg
Mean55.2 ± 11.66
Sex: Female, Male
Sex: Female, Male(Participants)Gemcitabine 2500 mg/m^2 + Bevacizumab 10 mg/kg
Female52
Male0
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Gemcitabine 2500 mg/m^2 + Bevacizumab 10 mg/kg
African descent11
Caucasian41
Region of Enrollment
Region of Enrollment(participants)Gemcitabine 2500 mg/m^2 + Bevacizumab 10 mg/kg
United States52
Estrogen Receptor (ER) Status
Estrogen Receptor (ER) Status(participants)Gemcitabine 2500 mg/m^2 + Bevacizumab 10 mg/kg
ER+33
ER-19
Progesterone Receptor (PR) Status
Progesterone Receptor (PR) Status(participants)Gemcitabine 2500 mg/m^2 + Bevacizumab 10 mg/kg
PR+30
PR-22
Human Epidermal Growth Factor Receptor 2 (HER2/neu)
Human Epidermal Growth Factor Receptor 2 (HER2/neu)(participants)Gemcitabine 2500 mg/m^2 + Bevacizumab 10 mg/kg
HER2/neu+0
HER2/neu-52
Eastern Cooperative Oncology Group (ECOG) Performance Status
Eastern Cooperative Oncology Group (ECOG) Performance Status(participants)Gemcitabine 2500 mg/m^2 + Bevacizumab 10 mg/kg
028
124
08

Study locations

16 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Fayetteville, Arkansas 72703, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Fresno, California 93720, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    San Diego, California 92121, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Longmont, Colorado 80501, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Fairfield, Connecticut 06824, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Augusta, Georgia 30901, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Lambertville, Michigan 48144, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    St Louis, Missouri 63141, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Great Falls, Montana 59405, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    New York, New York 10003, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Oklahoma City, Oklahoma 73112, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Columbia, South Carolina 29210, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Germantown, Tennessee 38138, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Nashville, Tennessee 37203, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Salt Lake City, Utah 84106, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Newport News, Virginia 23601, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2008, a primary completion of Jan 2011 and a completion of Jan 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2012, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 13, 2008
First posted
Feb 25, 2008
Start
Mar 2008
Primary completionActual
Jan 2011
CompletionActual
Jan 2011
Results first posted
Jan 9, 2012
Last update
Jan 9, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 9, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00623233
Collaborators
Genentech, Inc.
Responsible party
Sponsor
First posted
Feb 25, 2008
Start date
Mar 2008
Primary completion
Jan 2011
Completion
Jan 2011
Results posted
Jan 9, 2012
Last update
Jan 9, 2012

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern Time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Gemcitabine · Bevacizumab

Start the discussion